WO2012091465A3 - Monoclonal antibodies to serum amyloid a, and hybridoma cells producing same - Google Patents

Monoclonal antibodies to serum amyloid a, and hybridoma cells producing same Download PDF

Info

Publication number
WO2012091465A3
WO2012091465A3 PCT/KR2011/010260 KR2011010260W WO2012091465A3 WO 2012091465 A3 WO2012091465 A3 WO 2012091465A3 KR 2011010260 W KR2011010260 W KR 2011010260W WO 2012091465 A3 WO2012091465 A3 WO 2012091465A3
Authority
WO
WIPO (PCT)
Prior art keywords
hybridoma cells
monoclonal antibodies
serum amyloid
producing same
cells producing
Prior art date
Application number
PCT/KR2011/010260
Other languages
French (fr)
Korean (ko)
Other versions
WO2012091465A2 (en
Inventor
조제열
Original Assignee
(주)프로탄바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)프로탄바이오 filed Critical (주)프로탄바이오
Publication of WO2012091465A2 publication Critical patent/WO2012091465A2/en
Publication of WO2012091465A3 publication Critical patent/WO2012091465A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to monoclonal antibodies to serum amyloid A, and to hybridoma cells producing same. The hybridoma cells (10G1 and 1H1) and the monoclonal antibodies produced from the hybridoma cells according to the present invention provide higher levels of expression of serum amyloid A antigens (SAA1 and SAA2) in the serum of a lung cancer patient than in the serum of a healthy person. Therefore, both hybridoma cells (10G1 and 1H1) and the monoclonal antibodies produced from the hybridoma cells according to the present invention may have superior binding specificity to serum amyloid A antigens (SAA1 and SAA2).
PCT/KR2011/010260 2010-12-31 2011-12-28 Monoclonal antibodies to serum amyloid a, and hybridoma cells producing same WO2012091465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0140414 2010-12-31
KR1020100140414A KR101708651B1 (en) 2010-12-31 2010-12-31 Serum amyloid A specific monoclonal antibody and hybridoma cell producing the same

Publications (2)

Publication Number Publication Date
WO2012091465A2 WO2012091465A2 (en) 2012-07-05
WO2012091465A3 true WO2012091465A3 (en) 2012-08-23

Family

ID=46383732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/010260 WO2012091465A2 (en) 2010-12-31 2011-12-28 Monoclonal antibodies to serum amyloid a, and hybridoma cells producing same

Country Status (2)

Country Link
KR (1) KR101708651B1 (en)
WO (1) WO2012091465A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107860926A (en) * 2017-09-29 2018-03-30 北京市心肺血管疾病研究所 The blood serum designated object of one group of detection aortic aneurysm/dissection of aorta and its application
GB2568298A (en) * 2017-11-13 2019-05-15 Univ Stellenbosch Methods, systems and devices for detecting inflammation
CN110105448A (en) * 2019-05-10 2019-08-09 上海钹乐诗生物技术有限公司 A kind of preparation method of the anti-human SAA monoclonal antibody of source of mouse
US11802147B2 (en) * 2019-07-03 2023-10-31 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detecting amanitins
CN111289759B (en) * 2020-03-10 2023-10-27 苏州翊讯生物科技有限公司 SAA detection kit and SAA quantitative detection method
CN113189335A (en) * 2021-06-17 2021-07-30 上海中乔新舟生物科技有限公司 Application of serum amyloid A2 in preparation of lung cancer detection kit
CN113698479B (en) * 2021-07-30 2023-01-17 杭州博岳生物技术有限公司 Anti-serum amyloid A human-mouse chimeric monoclonal antibody
CN116836273B (en) * 2022-03-23 2024-03-08 东莞市朋志生物科技有限公司 Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09121888A (en) * 1995-11-06 1997-05-13 Cosmo Sogo Kenkyusho:Kk Monoclonal antibody
EP0872558A1 (en) * 1995-08-30 1998-10-21 Eiken Kagaku Kabushiki Kaisha Monoclonal antibody recognizing serum amyloid a
US20080160546A1 (en) * 2005-12-22 2008-07-03 Tracey Colpitts Methods and Marker Combinations for Screening For Predisposition to Lung Cancer
JP2008239511A (en) * 2007-03-26 2008-10-09 Japan Racing Association Monoclonal antibody, kit for determination of equine saa and method for diagnosis of equine inflammatory disease
KR100925147B1 (en) * 2009-04-27 2009-11-05 경북대학교 산학협력단 Markers for the diagnosis of lung cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872558A1 (en) * 1995-08-30 1998-10-21 Eiken Kagaku Kabushiki Kaisha Monoclonal antibody recognizing serum amyloid a
JPH09121888A (en) * 1995-11-06 1997-05-13 Cosmo Sogo Kenkyusho:Kk Monoclonal antibody
US20080160546A1 (en) * 2005-12-22 2008-07-03 Tracey Colpitts Methods and Marker Combinations for Screening For Predisposition to Lung Cancer
JP2008239511A (en) * 2007-03-26 2008-10-09 Japan Racing Association Monoclonal antibody, kit for determination of equine saa and method for diagnosis of equine inflammatory disease
KR100925147B1 (en) * 2009-04-27 2009-11-05 경북대학교 산학협력단 Markers for the diagnosis of lung cancer

Also Published As

Publication number Publication date
KR20120078192A (en) 2012-07-10
WO2012091465A2 (en) 2012-07-05
KR101708651B1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
WO2012091465A3 (en) Monoclonal antibodies to serum amyloid a, and hybridoma cells producing same
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
MX369148B (en) Kir3dl2 binding agents.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2012143524A3 (en) Bispecific antibodies against her2 and cd3
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2011160119A8 (en) Anti-gd2 antibodies
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
WO2011004028A3 (en) Tlr3 binding agents
WO2012012750A8 (en) Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2011130434A3 (en) Antibodies that bind human cd27 and uses thereof
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2011110642A3 (en) Monoclonal antibodies against c-met
UA95478C2 (en) Humanized c-kit antibody
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2012068405A3 (en) Modulation of alpha synuclein expression
AU2009260320A8 (en) Antibodies to IL-6 and their uses
IL206715A (en) Monoclonal anti mif antibodies, pharmaceutical compositions comprising them, their uses and methods of producing them
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
EA201892184A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
MX2010001237A (en) Novel antibodies.
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11852483

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24/10/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11852483

Country of ref document: EP

Kind code of ref document: A2